Myomo, Inc. (MYO)
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
$1.44+2.86%
Close 2026-09-04 · 1-day change
AMEXHealth CareMedical - DevicesSnapshot 2026-09-04
QuarterlyIQ Insights · MYO
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance recently climbed back into the top half of its industry — confirming the recovery.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | -68.7% |
| Our one-year growth estimate | diamond |
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
| 13.6% |
Growth built into the price is above our model estimate.
The price assumes 82.3 percentage points less one-year growth.
The one-year revenue growth assumption on Valuation.
Model as of 2026-09-04 · Compared with 87 industry peers · Company calendar date is not available
MYO — director transition
Dated 2026-05-13
Director — Joseph M. Manko Jr.: Appointment of Joseph M. Manko Jr. to the Board of Directors.
Why it matters: Keeping this margin shows good cost control and pricing power.
Supportive ifGross margin reported above 70%, confirming strong pricing and cost control.
Worry ifGross margin below 70% suggests possible cost issues.
Why it matters: Keeping revenue guidance is important. It helps set expectations and keeps investor confidence high.
Watch forManagement says quarterly revenue guidance is the same or better.
Also watch forManagement cuts its revenue forecast for the quarter.
Why it matters: Good comments on making money could show a change in financial health.
Watch forManagement says they plan to make money in the next year.
Also watch forManagement says there are delays or problems in making money.
Why it matters: Finishing new contracts helps market access. This can increase revenue growth.
Supportive ifNew in-network payer contracts were announced before Q2 earnings.
Worry ifNo new in-network payer contracts announced before Q2 earnings.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$457 on $10,000 · ±4.6% | How much price usually moves either way. |
| Bad day | $894 loss on $10,000 · 8.9% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,575 loss on $10,000 · 45.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Keeping costs low while increasing revenue is important. It helps improve operating income.
Supportive ifOperating costs are less than $10 million.
Worry ifOperating costs are more than $10 million.
Why it matters: More students would help create new products. This could lead to more money later.
Supportive ifEnrollment reaches or exceeds 50 subjects in the ongoing clinical trial.
Worry ifEnrollment stops or drops, showing problems in clinical research.
Why it matters: If revenue growth speeds up, it could signal a positive shift in the company's performance.
Supportive ifMyomo reports revenue growth above 10% year over year.
Worry ifRevenue growth remains below 10% year over year.
Why it matters: New contracts help expand market access. They can boost revenue growth.
Supportive ifNew payer contracts were announced. They increase in-network access to over 100 million covered lives.
Worry ifNo new payer contracts were announced. This shows stagnation in market access efforts.
Why it matters: Smaller losses mean better efficiency. This shows stronger finances.
Supportive ifAdjusted EBITDA loss reported less than $0.8 million in Q3.
Worry ifAdjusted EBITDA loss grows past $0.8 million. This shows operational problems.
Why it matters: Confirming the revenue guidance for Q3 shows the company is on track for growth. This can reassure investors about the company's performance.
Supportive ifQ3 revenue was between $11.5 million and $12.0 million. This shows 14% to 19% growth from last year.
Worry ifQ3 revenue is below $11.5 million. This may show problems with growth.
Why it matters: More recurring revenue means a stronger and more stable business. This can lead to better finances.
Supportive ifRecurring patient revenue exceeds 55% of total revenue in Q3 2026.
Worry ifRecurring patient revenue is below 53%. This suggests slower growth in this area.
Why it matters: Keeping operating costs steady while revenue grows shows good cost management. This can help make more money.
Supportive ifOperating expenses stay the same or drop in Q3 2026 compared to Q2 2026.
Worry ifOperating expenses are rising a lot. This may show some inefficiencies.
Why it matters: Successful enrollment in clinical trials can lead to new product approvals and market expansion. This is key for future growth.
Supportive ifEnrollment hits 50 subjects in the trial at the University of Utah.
Worry ifEnrollment stalls or fails to reach the target of 50 subjects.